Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
Publication Type:
Journal Article
Authors:
Berenguer, J.;
Álvarez-Pellicer, J.;
Martin, P.M.;
Lopez-Aldeguer, J.;
Von-Wichmann, M.A.;
Quereda, C.;
Mallolas, J.;
Sanz, J.;
Tural, C.;
Bellon, J.M.;
Gonzalez-Garcia, J.;
GESIDA3603/5607 study groupSource:
Hepatology, Volume 50, Issue 2, p.407-413 (2009)
Keywords:
Adult,
analysis,
Antiviral Agents,
Carcinoma,
Cohort Studies,
complications,
Disease,
drug therapy,
Drug Therapy,Combination,
End Stage Liver Disease,
Female,
Fibrosis,
Genotype,
HCV,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
history,
Hiv,
HIV Infections,
Human,
Humans,
Incidence,
Infection,
interferon,
Interferons,
Liver,
Liver Transplantation,
Male,
Mortality,
nonresponder,
Patients,
Prospective Studies,
Regression Analysis,
Research,
Research Support,
Ribavirin,
Rna,
Spain,
Survival,
sustained virologic response,
SVR,
therapeutic use,
therapy,
transplantation,
Treatment Outcome,
Viral Load
